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Preliminary evidence for association of genetic variants
in pri-miR-34b/c and abnormal miR-34c expression
with attention deﬁcit and hyperactivity disorder
I Garcia-Martínez1,2, C Sánchez-Mora1,2,3, M Pagerols1,2, V Richarte2,3,4, M Corrales1,2,4, C Fadeuilhe2, B Cormand5,6,7,8, M Casas1,2,3,4,
JA Ramos-Quiroga1,2,3,4 and M Ribasés1,2,3
Attention deﬁcit and hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by impairment to
sustain attention and inability to control impulses and activity level. The etiology of ADHD is complex, with an estimated heritability
of 70–80%. Under the hypothesis that alterations in the processing or target binding of microRNAs (miRNAs) may result in
functional alterations predisposing to ADHD, we explored whether common polymorphisms potentially affecting miRNA-mediated
regulation are involved in this psychiatric disorder. We performed a comprehensive association study focused on 134 miRNAs in
754 ADHD subjects and 766 controls and found association between the miR-34b/c locus and ADHD. Subsequently, we provided
preliminary evidence for overexpression of the miR-34c-3p mature form in peripheral blood mononuclear cells of ADHD subjects.
Next, we tested the effect on gene expression of single-nucleotide polymorphisms within the ADHD-associated region and found
that rs4938923 in the promoter of the pri-miR-34b/c tags cis expression quantitative trait loci for both miR-34b and miR-34c and has
an impact on the expression levels of 681 transcripts in trans, including genes previously associated with ADHD. This gene set was
enriched for miR-34b/c binding sites, functional categories related to the central nervous system, such as axon guidance or neuron
differentiation, and serotonin biosynthesis and signaling canonical pathways. Our results provide preliminary evidence for the
contribution to ADHD of a functional variant in the pri-miR-34b/c promoter, possibly through dysregulation of the expression of
mature forms of miR-34b and miR-34c and some target genes. These data highlight the importance of abnormal miRNA function as
a potential epigenetic mechanism contributing to ADHD.
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INTRODUCTION
Attention deﬁcit and hyperactivity disorder (ADHD) is a highly
prevalent neuropsychiatric disorder characterized by severe
impairment to sustain attention, inability to control impulses
and difﬁculties to modulate activity levels. Epidemiological studies
report a worldwide ADHD prevalence of 5–12% for children and
3–8% for adults.1 The etiology of ADHD is complex, with both
genetic and environmental factors having key roles.2 Twin, family
and adoption studies suggest a major component of genetic risk
factors, pointing to an estimated heritability around 70–80%.3 The
Psychiatric Genomics Consortium has recently shown direct,
empirical and quantiﬁed molecular evidence for a signiﬁcant
genetic contribution to ADHD and estimated a single-nucleotide
polymorphism (SNP)-based heritability of 0.28, which is distant to
the total ADHD heritability and highlights the need for additional
studies to unravel the ADHD genetic background.4
Although association, linkage and animal model strategies have
been followed to uncover the genetic background of ADHD,
consistent genetic risk factors with a major role in its susceptibility
have not yet been discovered.5 Pathogenic models of ADHD have
traditionally focused on the dysregulation of the dopaminergic,
serotoninergic and noradrenergic neurotransmission systems, the
regulation of neurotransmitter release (SNARE complex) and on
neurotrophic factors.6 In addition to candidate–gene association
studies, genome-wide association studies (GWAS) have also been
carried out in nine independent data sets in ADHD, seven of which
focused on childhood samples and two on adults.3,5,7,8 However,
none of them reported genome-wide signiﬁcant ﬁndings or
highlighted previous candidate genes for ADHD or identiﬁed
associations overlapping with those of other GWAS.
Research on ADHD has traditionally focused on protein-coding
sequences, but some data suggest that most of the common
phenotypic variation would stem from variants in regulatory
elements rather than in protein-coding sequences.9 Thus, there is
a growing interest into genetic variation affecting epigenetic
mechanisms involved in the dysregulation of gene expression.
Among them, microRNAs (miRNAs) have emerged as strong
candidates. These small non-coding single-stranded RNA mole-
cules have important gene-regulatory roles by pairing to the
messenger RNA (mRNAs) of protein-coding genes to direct their
posttranscriptional repression.10 Some observations, however,
suggest that miRNAs can also target other genomic regions, such
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as 5′-UTR elements, promoters or coding sequences, and
additionally they may even be able to stimulate gene expression.
The miRNAs conﬁgure a complex network where individually they
may regulate hundreds of genes and collectively they are
predicted to modulate from 30 to 80% of the human genome.11
Thus, slight variations affecting this system may lead to altered
miRNA function, have pleiotropic effects, and contribute to part of
the genetic heterogeneity underlying complex diseases. Interest-
ingly, around 70% of all known miRNAs are expressed in the brain
and have key roles in cell-fate speciﬁcation and survival, neurite
projection and synaptic plasticity.12 Moreover, miRNAs are known
to be implicated in psychiatric and neurological disorders. A GWAS
in schizophrenia revealed that the strongest association corre-
sponded to miR-137, and SNPs in multiple other miRNAs, such as
miR-206, miR-198, miR-24 or miR-30e, have also been associated
with this disorder.13,14 Abnormal miRNA biogenesis and expres-
sion levels have been observed in schizophrenia, bipolar or autism
spectrum disorder (ASD). Moreover, variants within the miR-183-
96-182 cluster locus or in the miR-641 binding sites at SNAP25
gene have been associated with ADHD and impulsivity,
respectively.15,16 In addition, a recent study reported altered
circulating levels of miRNAs in ADHD subjects and suggested that
miR-107 levels below a certain threshold were highly predictive
and speciﬁc for ADHD.17
Considering this background altogether, we attempted to
unravel novel susceptibility factors for ADHD by conducting a
case–control association study focused on miRNAs and their
target genes. We selected miRNAs based on the previous
association of their validated targets to psychiatric illness, giving
priority to those linked to ADHD. Subsequently, we conducted a
case–control association study in 754 adult ADHD subjects and
766 healthy controls. The impact of the associated variants on
gene expression was evaluated through analysis of Quantitative
Trait Loci (eQTLs) in cis and trans in the peripheral blood
mononuclear cells (PBMCs) from subjects with ADHD. Top hits
from the trans-eQTL results were considered for functional and
canonical pathway overrepresentation and gene-network
construction.
MATERIALS AND METHODS
Case–control association study
Subjects. The clinical sample consisted of 754 Caucasoid Spanish adults
with ADHD (61% combined, 36% inattentive and 3% hyperactive/
impulsive). Sixty-seven percent of the individuals were male and the
average age at assessment was 33 years (s.d. = 12.7). The evaluation of the
ADHD diagnosis was carried out with the Structured Clinical Interview for
DSM-IV Axis I and II Disorders (SCID-I and SCID-II) and with the Conners’
Adult ADHD Diagnostic Interview for DSM-IV (CAADID parts I and II).18 The
severity of ADHD symptoms was assessed with the long version of the
Conners’ ADHD Rating Scale (self-report [CAARS-S:L] and observer [CAARS-
O:L]),19 the ADHD rating scale,20 the ADHD screening checklist21 and the
Wender Utah Rating Scale for retrospective symptomatology.22 The level of
impairment was measured with the Clinical Global Impression and the
Sheehan Disability Inventory.23,24 Additional tests used for clinical
assessment are available in Ribasés et al.25 The control sample included
766 unrelated Caucasoid Spanish healthy individuals matched for sex with
the clinical group. Sixty-seven percent of the subjects were male with an
average age of 57 years (s.d. = 18.4). ADHD symptomatology was excluded
retrospectively under the following criteria: (1) not having been diagnosed
with ADHD previously and (2) answering negatively to the life-time
presence of the following ADHD symptoms: (a) often has trouble in
keeping attention on tasks; (b) usually loses things needed for tasks; (c)
often ﬁdgets with hands or feet or squirms in seat and (d) often gets up
from seat when remaining in seat is expected. All the subjects were
evaluated and recruited at the Hospital Universitari Vall d’Hebron of
Barcelona (Spain) and diagnosis was blind to genotype. The study was
approved by the ethics committee of our institution and written informed
consent was obtained from all the subjects before the inclusion into
the study.
DNA isolation, SNP selection and genotyping. Genomic DNA was isolated
from peripheral blood leukocytes by the salting-out procedure.
MiRNA and miRNA clusters: On the basis of literature data, 134
miRNAs distributed in 53 loci with at least one conﬁrmed target gene
involved in ADHD or other psychiatric disorders, including schizophrenia,
bipolar disorder, major depression and/or ASD, were selected from a total
of 5201 records of experimentally validated miRNA–target interactions
available at the miRecords database (release 2012).26 MiRNA clusters were
deﬁned as genomic regions containing at least two contiguous miRNAs
with an interdistance of o10 kb. Candidate regions spanned 5 kb
upstream and 3 kb downstream from each miRNA or from the ﬁrst and
last miRNA of each cluster. When miRNAs were located in a transcriptional
unit, some additional 5 kb upstream from the host gene were also
included.
MiRNA targets: The analysis of 3′-UTR regions was restricted to target
genes of those miRNAs displaying association with ADHD in the case–
control association study. Experimentally validated miRNA targets were
selected using information available in different databases, including
TargetScan (release 6.2), Diana-TarBase (version 7.2), miRTarBase (release
2014, version 6.0), miRBase (release 21) and miRecords (release 2012), or
through literature searches (Supplementary Table 1).26–29 Considering only
those mRNAs that are targeted by the miRNA found to be associated with
ADHD in this study, a total of 12 candidate genes were initially selected on
the basis of experimental data supporting each miRNA–mRNA interaction
(BCL2, CREB1, CRHR1, HMGA2, JAG1, MET, MYC, NOTCH1, NOTCH2, NOTCH3,
NOTCH4 and VEGFA; Supplementary Table 1).
Tagged-SNP selection was based on genetic coverage criteria (r2⩽ 0.85)
considering SNPs with a minor allele frequency (MAF) ⩾ 0.10 from the
CEPH population provided by the HapMap Project Database (http://
hapmap.ncbi.nlm.nih.gov/; release 28) and using the LDSelect Software
(http://bioapp.psych.uic.edu/HapMap-LDSelect-Processor.html, University
of Washington, Seattle, WA, USA). Under these conditions, we selected
214 tagSNPs covering, in terms of linkage disequilibrium (LD), genomic
regions containing 134 miRNAs. We also selected 20 SNPs that tag the 3′-
UTR regions of genes encoding mRNAs that are targeted by the miRNA
found to be associated with ADHD in this study. From the 12 target genes
initially selected, no SNPs at NOTCH4 or MYC fulﬁlled the aforementioned
criteria and, therefore, only 10 candidate genes were ﬁnally considered
(BCL2, CREB1, CRHR1, HMGA2, JAG1, MET, NOTCH1, NOTCH2, NOTCH3 and
VEGFA). An additional variant, rs4525537, reported in the 1000 Genomes
database (http://browser.1000genomes.org; release 14), was also included
owing to its close location to the miR-34c target site in the CRHR1 3′-UTR
(14 nucleotides upstream from the miRNA–mRNA binding site). From the
235 SNPs that were initially selected, a proper design was not achieved for
four of them, and in some additional 10, the genotyping assay failed
(genotyping rate of 97.5% for the miRNAs assay and 100% for the target
genes assay). All SNPs were genotyped using the PCR-based KASP platform
(Progenika Biopharma, A GRIFOLS Company, Bizkaia, Spain).
Statistical analysis
The minimal statistical power of the sample was estimated post hoc using
the Power Calculator for Two Stage Association Studies software (CaTS,
http://csg.sph.umich.edu//abecasis/CaTS/index.html), assuming an odds
ratio (OR) of 1.2, a disease prevalence of 0.05, a signiﬁcance level (α) of
0.05, the lowest MAF observed in our control sample (0.10), and an additive
model of inheritance. Potential genetic stratiﬁcation in our sample was
previously discarded.30
Single-marker analyses. The analysis of Hardy–Weinberg equilibrium
(HWE) in the control sample (PHWEo0.01) and the comparison of genotype
frequencies between cases and control subjects under a log-additive
model of inheritance were performed using the SNPassoc R Library.31
Dominant (11+12 vs 22) and recessive (11 vs 12+22) models of inheritance
were only considered for those SNPs displaying nominal association under
a log-additive model. Genotype frequencies of SNPs located in chromo-
some X were only studied in females. All the tests were adjusted by
gender. To measure and control the proportion of false positives incurred
in the study, we used the false discovery rate (FDR) method, an approach
to adjust for multiple comparisons that provides a good balance between
discovery of statistically signiﬁcant ﬁndings and controlling type I errors
(α). The q-value was computed using the qvalue R package32 considering
all the association tests performed for miRNAs and target genes jointly. We
considered all the P-values from each SNP tested under an additive model
of inheritance, as well as the P-values from the dominant and recessive
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models when considered (when the association under the additive model
was signiﬁcant (Po0.05)). Under these conditions, a total of 232 P-values
were included and a unique FDR of 20% that corresponded to
Po1.58e− 03 was considered.
Gene-based analysis. Gene-based association analysis was performed
using the Versatile Gene-based Association Study (VEGAS) 2 software
(https://vegas2.qimrberghofer.edu.au/).33 We considered all genomic
regions containing miRNA or target genes with more than one genotyped
SNP per region. All the genotyped SNPs available from each locus were
included in the analysis considering the nominal P-value of each
association test from the single-marker analysis. Regions were deﬁned
spanning 10 kb upstream and downstream from each locus, and European
samples from 1000 Genomes were used to assess their LD structure.
Analysis of additive and epistatic effects. To evaluate the potential additive
and epistatic effects between the identiﬁed risk variants, a stepwise logistic
regression procedure was implemented using the SPSS 17.0 Statistical
Package (SPSS, Chicago, IL, USA), considering the overall, the combined or
the inattentive samples as dependent variables and the ADHD-risk variants
as independent variables. The hyperactive-impulsive sample was not
considered, owing to its limited sample size.
Gene expression assays
RNA isolation. Total RNA was extracted from PBMCs of a medication-naive
subset of 45 ADHD individuals from the sample included in the case–
control association study (68% were male and mean age was 38 years (s.
d. = 9.9)) and from 32 additional control subjects (69% were male and
mean age was 37 years (s.d. = 12.1)) using the Ficoll density gradient
method and the RNeasy Midi kit (Qiagen, Hilden, Germany). RNA and
miRNA quality assessment was assayed by 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA).
Expression analysis of miR-34b and miR-34c by quantitative real-time reverse
transcription in ADHD subjects and controls. In 31 out of the 45 cases
mentioned above, the total RNA isolation protocol from PBMCs was
performed with further enrichment of miRNAs. Considering only the
miRNA found signiﬁcantly associated with ADHD in this study, the
expression levels of the mature forms miR-34b-3p, miR-34b-5p, miR-34c-3p
and miR-34c-5p were assessed in these 31 cases and in 32 additional
control subjects by reverse transcription reaction using the Taqman
MicroRNA Reverse Transcription Kit (Applied Biosystems; Foster City, CA,
USA). Quantitative real-time reverse transcription PCR (qRT-PCR) for each
assay was run in triplicate using Taqman MicroRNA Assays (Applied
Biosystems) and measured in Applied Biosystems 7900HT fast real-time
PCR system. The threshold cycle (CT) was deﬁned as the fractional cycle
number at which the ﬂuorescence exceeded the threshold of 0.2. The
relative quantiﬁcation of miRNA expression was calculated by the 2−ΔΔCT
method,34 considering U6 as endogenous control gene after checking its
stability and linearity across all the samples. Batch, gender and age were
considered as covariates when a signiﬁcant association with the study
outcome was observed (P40.20) and were kept in the statistical model if
the corresponding equation parameter was signiﬁcant in the ﬁtted model
(Po0.05). Logistic regression models were applied to compare expression
differences between ADHD cases and controls. All the statistical tests were
two-sided and the signiﬁcance threshold was set at Po0.05.
Cis-eQTLs in ADHD subjects by qRT-PCR. The cis-eQTL analyses were
assessed in the subset of 31 ADHD subjects from which genotype data for
rs4938723 and rs28690953 and expression levels of miR-34b-3p, miR-34b-
5p, miR-34c-3p and miR-34c-5p were available. Linear regression models
were used for eQTL mapping with the SPSS 17.0 Statistical Package (SPSS).
All the statistical tests were two-sided and the signiﬁcance threshold was
set at Po0.05.
Trans-eQTLs in ADHD subjects by microarray assay. Genome-wide gene
expression data from microarray assays was used for the trans-eQTL
analyses in 45 ADHD subjects (60% overlap with the ADHD sample
included in the qRT-PCR assays). RNA was reverse transcribed using the
Ambion WT Expression Kit (Life Technologies, Carlsbad, CA, USA). The
cRNA was subsequently fragmented, labeled and hybridized with the
GeneChip WT Terminal Labeling and Hybridization Kit (Affymetrix, Santa
Clara, CA, USA). The samples were hybridized to the Genechip Human
Gene 1.1 ST 96-Array plate (Affymetrix), covering a total of 36 079
transcripts that correspond to 21 014 genes. The array processing and data
generation were assessed using the Gene Titan Affymetrix microarray
platform. The raw data were pre-processed with the Robust Multichip
Analysis method (including the background correction, normalization and
summarization of probes values) using the R environment and the Oligo
library.35 Transcript probes that did not correspond to known genes or
matched with more than one gene in the GRCh37/hg19 human genome
build (release 32) were discarded, and the study was ﬁnally restricted to
19 263 probes corresponding to 18 475 unique genes. Trans-eQTL analyses
considering rs4938723 were performed with the R environment and the
MatrixEQTL Package,36 including gender and batch as covariates. FDR
correction was applied for multiple comparisons and statistical signiﬁcance
was set at Po0.05.
Functional- and pathway-enrichment analyses. MiRNA binding-site enrich-
ment was explored using the WEB-based GEne SeT AnaLysis (WebGestalt)
Toolkit (http://bioinfo.vanderbilt.edu/webgestalt/).37 Functional and cluster
overrepresentation analyses were performed considering Biological
Process category from Gene Ontology using the Database for Annotation,
Visualization and Integrated Discovery resource (http://david.abcc.ncifcrf.
gov/).38 Evaluation of overall enrichment in direct and indirect interactions
between encoded proteins from our gene set was addressed with Disease
Association Protein-Protein Link Evaluator software (http://www.broad
institute.org/mpg/dapple/dapple.php).39 Enrichment analysis of canonical
pathways and gene networks were performed using the Ingenuity
Pathway Analysis software (Ingenuity Systems, Redwood City, CA, USA;
http://www.ingenuity.com). Gene networks were considered of true
relevance when the network score (P-score =− log10(P-value)) was over 3
(P=10− 3) and the total number of focus molecules was above 20 out of
35. Benjamini–Hochberg’s correction was used to adjust for multiple
comparisons and signiﬁcance threshold was set at Po0.05.
RESULTS
Case–control association study between ADHD and genomic
regions containing miRNAs or target genes
Assuming an OR of 1.2, the ADHD sample showed minimum
statistical powers of 36%, 27% and 20% in the overall, combined
and inattentive ADHD samples, respectively.
Single-marker and gene-based analyses
MiRNA and miRNA clusters: We studied 214 tagSNPs in 53
genomic regions spanning 143 miRNAs chosen on the basis of
convergent evidence of the involvement of their target genes in
ADHD or other psychiatric disorders in a total sample of 754 adults
with ADHD and 766 controls. From the 203 successfully
genotyped SNPs, eight were monomorphic (MAFo0.10) and
three had signiﬁcant departure from HWE in the control sample
(PHWEo0.01; Supplementary Table 2). After ﬁltering for low call
rate (subjects with o90% of successfully genotyped SNPs) or
gender discrepancy, a total of 23 individuals were discarded and,
therefore, 192 SNPs with an average genotype call rate of 97.5%
were ﬁnally considered in 748 cases and 749 controls.
When the whole ADHD sample was considered, nominal
associations were found for eight SNPs located at ﬁve loci: the
miR-128-2 locus and the clusters let-7a-1/let-7 f-1/let-7d, let-7a-3/
miR-4763/let-7b, miR-34b/c and miR-371/372/373 (Table 1a). None
of them was located in the mature or precursor forms of the
miRNAs and only rs28690953 within the miR-34b/c locus, 186 bp
downstream of MIR34C gene, remained associated with ADHD
after the FDR correction (P= 8.8e− 04 under a dominant model;
Supplementary Figure 1). The gene-based analysis supported the
association between miR-34b/c and let-7a-1/let-7f-1/let-7d clus-
ters and ADHD (P= 2.8e− 03 and P= 2.9e− 03, respectively;
Supplementary Table 3a).
MiRNA targets: We tested the association between ADHD and
tagSNPs covering 3′-UTRs of 10 experimentally validated target
genes for miR-34b and/or miR-34c (BCL2, CREB1, CRHR1, HMGA2,
JAG1, MET, NOTCH1, NOTCH2, NOTCH3 and VEGFA). Of the 21 SNPs
initially selected, three did not pass through the design pipeline,
miR-34b/c and attention deﬁcit/hyperactivity disorder
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one was monomorphic (MAFo0.10) and another had signiﬁcant
departure from HWE (PHWEo0.01; Supplementary Table 4). After
ﬁltering subjects with low call rate (o90%), a total of 24
individuals were discarded and, therefore, 16 SNPs with an
average genotype call rate of 97.5% were ﬁnally considered in 751
ADHD cases and 745 controls. The single-marker analysis showed
nominal association between ADHD and four SNPs in three genes:
rs1621 and rs6566 within the MET gene (P= 8.3e− 03, OR= 1.23
(1.06− 1.44) and P= 0.017, OR = 1.19 (1.03− 1.39), respectively),
rs699779 in the NOTCH2 gene (P= 7.7e− 03; OR = 3.45
(1.28− 9.09)) and rs1175982 in the HMGA2 gene (P= 7.5e− 03;
OR= 1.34 (1.08− 1.67); Table 1b, Supplementary Figure 1). None of
them withstood FDR correction for multiple comparisons. The
gene-based analysis supported the association between ADHD
and the MET and HMGA2 genes (P= 5.6e− 03 and P= 7.1e− 03,
respectively; Supplementary Table 3b). NOTCH2 was not consid-
ered as it contained only one marker.
Analysis of additive and epistatic effects. As ADHD was associated
with SNPs in the miR-34b/c cluster and in the 3′-UTRs of three
validated target genes (MET, NOTCH2 and HMGA2), we further
tested potential additive and epistatic effects among them. The
combined effect of all ADHD risk variants was estimated to
account for 3.2 and 4.5% of the variance of the overall
(P= 1.2e− 06) and combined ADHD (P= 3.4e− 07), respectively,
which resulted in sensibility and speciﬁcity values over 55%. No
signiﬁcant interactions between miR-34b/c and any of the targets
genes were detected.
Gene expression assays
Expression analysis of miR-34b and miR-34c by qRT-PCR in ADHD
subjects and controls. Expression levels of the mature forms of
miR-34b and miR-34c were evaluated by qRT-PCR in PBMCs from
31 medication-naive ADHD individuals and 32 controls. Signiﬁcant
overexpression of miR-34c-3p was identiﬁed in ADHD subjects
(P= 6.5e− 03; Exp(B) = 4.19; CI = 1.25–14.05), with 1.4-fold higher
levels in patients as compared with controls. MiR-34b-3p also
showed a trend towards increased expression in ADHD when
compared with controls (P= 0.058; Exp(B) = 2,70; CI = 0.89–8.20)
and no differences were observed for miR-34b-5p or miR-34c-5p.
Identiﬁcation of cis-eQTLs in ADHD subjects by qRT-PCR. To
determine whether expression differences in miR-34b and
miR-34c resulted from allele-speciﬁc differences in the identiﬁed
ADHD-associated risk locus, we searched for cis-eQTLs in PBMCs
from a subset of 31 ADHD subjects from whom miR-34b/c
genotypes and qRT-PCR expression data were available. Interest-
ingly, a signiﬁcant inverse correlation between the dosage of the
rs4938723T allele in the promoter region of the primary transcript
of miR-34b/c (pri-miR-34b/c) and expression levels of miR-34b-3p
and miR-34c-3p was observed (P= 0.021, β=− 0.41 and P= 0.027,
β=− 0.44, respectively; Figure 1). No differences were detected
for miR-34b-5p and miR-34c-5p or when rs28690953 was
considered.
Identiﬁcation of trans-eQTLs in ADHD subjects by microarray
assay. Next, we performed a transcriptome-wide trans-eQTL
analysis considering the dosage of the cis-associated rs4938723T
allele and microarray expression data from PBMCs of 45 ADHD
subjects, which revealed 681 differentially expressed transcripts,
292 of which were upregulated and 389 downregulated (Po0.05;
Supplementary Table 5). Among them, we identiﬁed genes
previously associated with ADHD in candidate–gene association
studies and GWAS, such as SYT2, HTR2C, SHFM1, DCLK1, TMX3,
BDNF, VAMP2 or TPH2 (Supplementary Table 6).
Functional- and pathway-enrichment analyses. Overrepresenta-
tion of miR-34b binding sites (P= 1.64e− 03; Supplementary Table
7) as well as enrichment for indirect protein–protein interactions
(seed indirect degrees mean = 55.11, P= 0.042) were identiﬁed
considering the 681 differentially expressed transcripts from the
trans-eQTL analyses (data not shown). Functional enrichment
analyses revealed 36 categories nominally associated with our
gene set, mainly related to lipid metabolism, and neuron
dynamics and axonogenesis (Supplementary Table 8). Accord-
ingly, the functional clustering showed two signiﬁcantly enriched
groups related to neuron development and differentiation, and
axonogenesis (score = 1.6), and lipid biosynthesis and metabolism
(score = 1.5; Supplementary Table 9). We also identiﬁed enrich-
ment for categories related to psychiatric disorders such as
‘susceptibility to attention deﬁcit/hyperactivity disorder’
(P= 0.032), ‘refractory schizophrenia’ (P= 0.032), major affective
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disorder (P= 0.032), ‘susceptibility to anorexia nervosa type II’
(P= 0.032) or ‘susceptibility to bulimia nervosa type II’ (P= 0.032),
as well as for neurologic diseases such as ‘Huntington disease
grade II’ (P= 0.032; data not shown). In addition, 12 canonical
pathways were overrepresented in the gene set, among which we
highlight ‘Serotonin and Melatonin Biosynthesis’ (P= 9.33e− 03)
and ‘Serotonin Receptor Signaling’ (P= 0.046; Figure 2). Interesting
biological functions were also found enriched, such as ‘synthesis
of neurotransmitter’ (P= 0.013), ‘release of neurotransmitter’
(P= 8.43e− 03), ‘inﬂux of dopamine’ (P= 0.032), ‘release of GABA’
(P= 0.032), ‘synthesis of 5-hydroxytryptamine’ (P= 9.32e− 03),
‘recycling of synaptic vesicles’ (P= 0.032) or ‘declarative memory’
(P= 0.032; data not shown). We also identiﬁed 20 signiﬁcant
networks, three of which had more than 20 focus molecules. The
best generated network was highly scored (score = 37; focus
molecules = 28), had follicle stimulating hormone as a central
node and displayed 312 speciﬁc overrepresented functions and
diseases (Figure 3, Supplementary Table 10).
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DISCUSSION
Under the hypothesis that alterations affecting the expression,
processing or target binding of miRNAs may result in functional
alterations predisposing to ADHD, we explored whether common
SNPs potentially affecting miRNA-mediated regulation are
involved in this psychiatric disorder.
We found association between a sequence variant within the
miR-34b/c locus and ADHD and provided preliminary evidence for
overexpression of the miR-34c-3p mature form in PBMCs of ADHD
subjects. We also assessed whether SNPs in the ADHD-associated
locus that contains miR-34b/c were involved in the disorder
through an effect on miRNA expression and found that rs4938723,
located in the promoter region of the pri-miR-34b/c, tags cis-eQTLs
for miR-34b-3p and miR-34c-3p. The rs4938723T allele dosage was
associated with decreased expression levels of the mature forms
of miR-34b and miR-34c in PBMCs of ADHD subjects, which is in
concordance with previous studies showing correlation between
the rs4938723C allele and a signiﬁcant increase in luciferase
activity.40 Interestingly, this sequence variant is located within a
CpG island, 423 bp upstream from the transcription start site of
this cluster of miRNAs, and may affect a predicted GATA-binding
site.40
Recent investigations link miRNAs to psychiatric disorders
including ADHD, schizophrenia, ASD, bipolar disorder and major
depressive disorder.14,16,41 Speciﬁcally, although it has crucial roles
in tumorigenesis, the miR-34 family participates in neuronal
development, stem cell differentiation, ageing, spermatogenesis,
as well as in metabolic and cardiovascular functions, and has been
implicated in noncancerous diseases such as brain disorders,
osteoporosis or cardiovascular complications.42 MiR-34b and
miR-34c have been found downregulated in the amygdala,
substantia nigra and frontal cortex in Parkinson’s disease and
have been linked to Alzheimer, anxiety or preclinical manifestation
of Huntington’s disease.43–46 Regarding psychiatric illness,
miR-34a dysregulation has been associated with bipolar disorder,
schizophrenia and major depressive disorder and a recent study
reported aberrant expression of miR-34b and miR-34c in the
peripheral blood of subjects with ASD.47–50
In addition to genetic variants in miRNAs, we focused our case–
control association study on several validated targets of miR-34b/c
and found signiﬁcant associations of ADHD with MET, HMGA2 and
NOTCH2 genes. Although not being previously related to ADHD,
MET and NOTCH2 have emerged as candidate genes for ASD.51,52
The MET gene might also be involved in schizophrenia, is highly
expressed in the developing brain and has been implicated in
GABAergic neuronal development, cortical thickness and con-
nectivity in temporal–parietal regions affecting the Default Mode
Network.51,53–55 The MET gene is known to mediate the
association between air pollution and cognitive development,
and independent studies have reported gene–environment
interactions between MET gene variants and exposure to air
pollutants in ASD.56 Importantly, as ADHD and ASD often co-occur
and share neuropsychological features, neurobiological substrates
and increased risk after exposure to air pollutants, further studies
are warranted to disentangle the role of MET gene in the
overlapping genetic background between these disorders.4,57
The transcriptome-wide trans-eQTL analysis considering the
rs4938723 miR-34b/c polymorphism highlighted 681 transcripts,
including genes previously implicated in ADHD. This gene set was
mainly related to neurotransmission, neuron development and
differentiation, axonal growth and guidance, cellular morphology
and projection, as well as to lipid biosynthesis and metabolism,
which is of particular importance in central nervous system (CNS)
injuries and psychiatric disorders including ADHD.58,59 Among the
top three genes, we found Synaptotagmin 2 (SYT2), an essential
component of the calcium-triggering machinery for neurotrans-
mitter release that was found associated with ADHD.60 As
expected, among the trans-eQTLs, we also found experimentally
validated miR-34b/c target genes, such as NOTCH3, enrichment for
miR-34b/c binding sites, including predicted targets in ADHD-
associated genes such as HTR2C and VAMP2, and genes related to
different psychiatric disorders including schizophrenia, major
affective disorder or eating disorders.5 Taken together, these data
reinforce a possible scheme for miR-34b/c having a role in adult
ADHD etiopathogenesis through a multifactorial mechanism
integrating miRNAs as well as genes previously associated with
ADHD and/or other psychiatric conditions.
There are several methodological considerations, however, that
should be discussed. (1) The results of the present association
study should be considered preliminary until further replication in
additional cohorts. In this regard, we explored results of the ADHD
GWAS meta-analysis from the Psychiatric Genomics Consortium
and observed no signiﬁcant association between rs28690953 or
rs4938723 and ADHD (P= 0.56 and P= 0.33, respectively). Hetero-
geneity between populations, methodologies and statistical tests
may explain discordant results across studies, making it difﬁcult to
reproduce the same ﬁndings and to establish direct comparisons
between reports. Our study included only adult ADHD patients
from Spain, whereas the Psychiatric Genomics Consortium sample
consists mainly of children and adolescent Caucasians of
European ancestry. These age differences as well as differential
proportion of remitting and persisting ADHD subjects between
samples may account for inconsistencies. Other explanations
could also contribute to these discordant results, such as sample
size, comorbid disorders as well as the proportions of clinical
subtypes or genders. In addition, our ﬁndings regarding miR-34b
and mirR-34c expression levels also require replication in a larger
and independent cohort as the limited sample size considered
may have led to imprecise estimates of the magnitude of the
miRNA expression differences and could have prevented us from
detecting signiﬁcant differences for miR-34b, which only displayed
a trend towards signiﬁcance. (2) The modest sample size of the
association study may have prevented us from detecting
susceptibility loci with very small effects in ADHD. In addition,
although the study was designed to assure a full genetic coverage
in terms of LD, the minimum MAF threshold was set at 0.10, which
may also have led to an underestimation of the contribution of
less common sequence variants. (3) Our inability to detect, in the
single-marker analysis, the association between ADHD and
rs4938723 that tags eQTLs for miR-34b and miR-34c, may be
attributed to the complex genetic background of ADHD as well as
potential gene-by-environment interactions, which might be
particularly relevant in ADHD. (4) As one of the tagSNPs in the
miR-34b/c locus could not be tested owing to experimental
constraints, it is still possible that additional sequence variants in
the region may contribute to the dysregulation of miR-34b and/or
miR-34c. (5) The selection of the FDR approach as the multiple-
testing correction method rather than other more conservative
strategies, such as Bonferroni, was based on the fact that the latter
may be too stringent to identify subtle genetic factors involved in
the etiology of a complex disease. In addition, the Bonferroni
correction requires independence between all performed tests
and, therefore, may be too restrictive in our study as some of the
selected SNPs show some degree of LD (LD threshold: r2 = 0.85),
and the different inheritance models tested for some of the SNPs
are not fully independent. (6) Although SNPs in 3′-UTR regions
that are targeted by miR-34b or miR-34c were selected solely on
the basis of genetic coverage criteria, prediction of the functional
signiﬁcance of the ADHD risk variants in MET, NOTCH2 and HMGA2
genes supports their impact on miRNA target site recognition but
none of them involved miR-34. (7) As we limited the gene
expression analyses to miRNAs and SNPs showing signiﬁcant
evidence for association with ADHD, we cannot rule out the
contribution to ADHD of other variants affecting the processing or
target binding of miRNAs. (8) All the participants were recruited by
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a single clinical group in a restricted geographic area (Barcelona),
and the diagnosis of ADHD was based on structured interviews
with no variability in measurements across data. In addition,
expression patterns were assessed in medication-naive subjects
with no comorbid disorders, which may facilitate the identiﬁcation
of ADHD-related transcriptional signatures that might be
neglected by a broader recruitment strategy. (9) The expression
experiments were performed in PBMCs and, therefore, further
evidence in brain tissues is required to disentangle the involve-
ment of miR-34b and miR-34c in ADHD. It is worth pointing out,
however, that the expression proﬁling of miRNAs shows correla-
tion between brain and PBMCs, where both tissues cluster
together based on the pattern of miRNA expression.61 A recent
meta-analysis also showed that cis-eQTLs in the peripheral blood
and brain display strong overlap and that there is solid evidence
supporting PBMCs as a proxy to study transcriptional and
epigenetic biosignature in different psychiatric disorders.62 Con-
sistently, at the transcriptome level, whole blood also shares
signiﬁcant gene expression similarities with multiple CNS tissues,
suggesting that the use of peripheral gene expression may be a
useful surrogate for gene expression in the CNS.63 Furthermore,
similarities between the mechanisms of transduction and receptor
expression in cells of the CNS and blood lymphocytes have also
been described.64 In this sense, disturbances in cellular functions
and metabolism in the CNS, as well as alterations in the major
neurotransmitter and hormonal systems, have been identiﬁed in
neuropsychiatric disorders concomitant with altered functioning
and metabolism of lymphocytes, which also support that the latter
could reﬂect the metabolism in brain cells.64,65
In conclusion, to our knowledge, this is the ﬁrst comprehensive
attempt to evaluate whether miRNAs are involved in ADHD and
we identiﬁed sequence variants in the pri-miR-34b/c associated
with ADHD and with expression levels of the mature forms of
miR-34b and miR-34c in ADHD subjects. This work increases the
understanding of biological mechanisms by which epigenetic
functions may contribute to ADHD and highlights the importance
of miRNAs in the etiology of the disorder.
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